secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2021-09-02T23:59:59+00:00
Accession:  0001437749-21-021383
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma reports FY net income $8.0M, revenue up 20.5% YoY
----------------------------------------------------------------------

- Revenue for FY ended June 30, 2021: $63.6M, up 20.5% YoY from $52.8M.
- FY net income $8.0M ($0.27 basic EPS) vs $4.1M ($0.14 basic EPS) prior year.
- Q4 revenue $17.1M (+26.7% YoY); Q4 net income $4.5M ($0.15 basic EPS) vs $1.9M ($0.06).
- FY operating income $5.8M vs $3.3M prior year; PPP forgiveness of $1.7M boosted other income.
- Two customers represent ~92% of total revenue in both FY2021 and FY2020, per co-CEOs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774921021383/0001437749-21-021383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774921021383/inbp20210902_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-21-021383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer